Metabolomics and detection of colorectal cancer in humans: a systematic review.
暂无分享,去创建一个
C. Slupsky | R. Fedorak | Carolyn M Slupsky | Richard N Fedorak | Haili Wang | Victor K Tso | Haili Wang | V. Tso
[1] Oliver Fiehn,et al. A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.
[2] Jing Hong,et al. Technology of metabonomics and its application in gastrointestinal cancer , 2008 .
[3] Oliver Fiehn,et al. Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover , 2008, Molecular Cancer.
[4] Donald G Robertson,et al. Metabonomics in toxicology: a review. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[5] R Somorjai,et al. Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts , 2009, NMR in biomedicine.
[6] A. Zell,et al. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients , 2008 .
[7] Tianlu Chen,et al. Urinary metabonomic study on colorectal cancer. , 2010, Journal of proteome research.
[8] Rachel Cavill,et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.
[9] Tianlu Chen,et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. , 2009, Journal of proteome research.
[10] Daniel Monleón,et al. Metabolite profiling of fecal water extracts from human colorectal cancer , 2009, NMR in biomedicine.
[11] T. Kieber‐Emmons,et al. Applying in vitro NMR spectroscopy and 1H NMR metabonomics to breast cancer characterization and detection , 2005 .
[12] Kevin F Krenitsky,et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection , 2010, BMC medicine.
[13] Leo L. Cheng,et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. , 2005, Cancer research.
[14] Douglas B Kell,et al. Metabolomic biomarkers: search, discovery and validation , 2007, Expert review of molecular diagnostics.
[15] R. Weinshilboum,et al. Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.
[16] K. Krishnan,et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia , 2007, Molecular Psychiatry.
[17] Douglas K Rex,et al. American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2022 .
[18] A. Neville,et al. Cost‐effectiveness of colorectal cancer screening: Comparison of community‐based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy , 2004, Journal of gastroenterology and hepatology.
[19] A. Imperiale,et al. Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy , 2009, Metabolomics.
[20] R. Hunt,et al. Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] I. Bertini,et al. Metabolomics: available results, current research projects in breast cancer, and future applications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Jostein Halgunset,et al. Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy , 2008, Molecular Cancer.
[23] P. Bossuyt,et al. BMC Medical Research Methodology , 2002 .
[24] Roberto Canaparo,et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. , 2004, Pharmacological research.
[25] J. Habbema,et al. Population Screening for Colorectal Cancer: Faeces, Endoscopes or X-Rays? , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[26] A. Ciampi,et al. Adherence to colorectal cancer screening guidelines in Canada , 2007, BMC gastroenterology.
[27] R. Hilsden,et al. Low Uptake of Colorectal Cancer Screening 3 Yr After Release of National Recommendations for Screening , 2007, The American Journal of Gastroenterology.
[28] T. Bathen,et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status , 2007, Breast Cancer Research and Treatment.
[29] A. Zell,et al. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. , 2008, Analytica chimica acta.
[30] Ya-li Liu,et al. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. , 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[31] D. Kell,et al. Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.
[32] L. Rabeneck,et al. A Population-Based Estimate of the Extent of Colorectal Cancer Screening in Ontario , 2004, American Journal of Gastroenterology.
[33] Elaine Holmes,et al. Topographical variation in metabolic signatures of human gastrointestinal biopsies revealed by high-resolution magic-angle spinning 1H NMR spectroscopy. , 2007, Journal of proteome research.
[34] Quantitative Pathology in Tissue MR Spectroscopy Based Human Prostate Metabolomics , 2004, Technology in cancer research & treatment.
[35] C. Mountford,et al. Assessment of human colorectal biopsies by 1H MRS: Correlation with histopathology , 1993, Magnetic resonance in medicine.
[36] David I. Ellis,et al. Metabolomics: Current analytical platforms and methodologies , 2005 .
[37] Ian D Wilson,et al. Analytical strategies in metabonomics. , 2007, Journal of proteome research.